Literature DB >> 2223586

Survival of intravenous chemotherapy infusion sites.

J F Hecker1.   

Abstract

Factors associated with the failure of intravenous infusions due to phlebitis and extravasation were studied with 218 infusions delivering cytotoxic drugs. The survival rate of these infusions was not significantly different from that of 56 non-cytotoxic infusions in oncology patients. Although survival analysis indicated that cisplatin was associated with longer survival, this was probably an artifact caused by this drug usually being preceded by 24 h prehydration. Multivariate analysis indicated that etoposide was the only drug associated with decreased infusion survival and that bleomycin, cyclophosphamide, doxorubicin, ifosphamide, methotrexate, treosulphan and 5-fluorouracil had no significant effects. Also age of patient, infusion site and flow rate had no effects but survival was shorter in women. Follow-up indicated that failure of an infusion tended to result in loss of the vein. It is suggested that irritancy of the large volumes of intravenous fluids given to hydrate these patients rather than the cytotoxic drugs was the main factor reducing the survival of these infusions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223586      PMCID: PMC1971472          DOI: 10.1038/bjc.1990.351

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Management and prevention of infiltration and extravasation injury.

Authors:  D J Lynch; J C Key; R R White
Journal:  Surg Clin North Am       Date:  1979-10       Impact factor: 2.741

2.  Failure of intravenous infusions from extravasation and phlebitis.

Authors:  J F Hecker
Journal:  Anaesth Intensive Care       Date:  1989-11       Impact factor: 1.669

3.  The pH and osmolality of intravenously used drugs.

Authors:  J W Mostert
Journal:  JAMA       Date:  1971-05-31       Impact factor: 56.272

4.  The pH and acidity of intravenous infusion solutions.

Authors:  M H Lebowitz; J Y Masuda; J H Beckerman
Journal:  JAMA       Date:  1971-03-22       Impact factor: 56.272

5.  Thrombophlebitis: incidence using standard versus buffered intravenous solutions. A study.

Authors:  C H Flores-Vega; J A Nuetzel; W A Knight
Journal:  Mo Med       Date:  1970-05

6.  Major intravenous extravasation injuries.

Authors:  J Upton; J B Mulliken; J E Murray
Journal:  Am J Surg       Date:  1979-04       Impact factor: 2.565

7.  The influence of heparin on intravenous infusions: a prospective study.

Authors:  W A Tanner; P V Delaney; T P Hennessy
Journal:  Br J Surg       Date:  1980-05       Impact factor: 6.939

8.  Complications of intravenous therapy: reduction by buffering of intravenous fluid preparation.

Authors:  O Eremin; V Marshall
Journal:  Med J Aust       Date:  1977-10-15       Impact factor: 7.738

9.  Steel needles used for intravenous therapy. Morbidity in patients with hematologic malignancy.

Authors:  J D Band; D G Maki
Journal:  Arch Intern Med       Date:  1980-01

10.  Amelioration of adriamycin skin necrosis: an experimental study.

Authors:  M H Cohen
Journal:  Cancer Treat Rep       Date:  1979-06
View more
  3 in total

Review 1.  Potential for extending survival of peripheral intravenous infusions.

Authors:  J F Hecker
Journal:  BMJ       Date:  1992-03-07

2.  Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.

Authors:  A M E Bruynzeel; M A Abou El Hassan; C Schalkwijk; J Berkhof; A Bast; H W M Niessen; W J F van der Vijgh
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

3.  The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.

Authors:  M A I Abou El Hassan; H M W Verheul; A S Jorna; C Schalkwijk; J van Bezu; W J F van der Vijgh; A Bast
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.